Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fulcrum Therapeutics, Inc. - Common Stock (NQ:FULC)

7.232 +0.112 (+1.58%)
Streaming Delayed Price Updated: 9:36 AM EDT, Jun 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fulcrum Therapeutics, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Fulcrum Therapeutics Earnings Preview
Fulcrum Therapeutics (NASDAQ:FULC) is set to give its latest quarterly earnings report on Tuesday, 2022-11-08. Here's what investors need to know before the announcement. Analysts estimate that Fulcrum... 
Via Benzinga
Fulcrum Therapeutics® to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Tuesday, November 8, 2022 at 8:00 a.m. ET
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics® to Participate at Upcoming November Investor Conferences
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Recap: Fulcrum Therapeutics Q2 Earnings
  Fulcrum Therapeutics (NASDAQ:FULC) reported its Q2 earnings results on Thursday, August 11, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
4 Analysts Have This to Say About Fulcrum Therapeutics
Within the last quarter, Fulcrum Therapeutics (NASDAQ:FULC) has observed the following analyst ratings: 
Via Benzinga
Analyst Ratings for Fulcrum Therapeutics
Within the last quarter, Fulcrum Therapeutics (NASDAQ:FULC) has observed the following analyst ratings: 
Via Benzinga
Why Super Micro Computer Shares Jumped Over 10%; Here Are 73 Biggest Movers From Yesterday
Gainers NextPlay Technologies, Inc. (NASDAQ: NXTP) shares climbed 107.3% to close at $0.4138 on Thursday after the company announced its NextFintech division received commitment for a $15 million... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers ASLAN Pharma (NASDAQ:ASLN) stock moved upwards by 13.7% to $0.54 during Wednesday's after-market session. The market value of their outstanding shares is at $37.6 million. 
Via Benzinga
Recap: Fulcrum Therapeutics Q1 Earnings
Fulcrum Therapeutics (NASDAQ:FULC) reported its Q1 earnings results on Monday, May 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Why Ericsson Shares Are Trading Lower? Here Are 56 Stocks Moving In Thursday's Mid-Day Session
Gainers NextPlay Technologies, Inc. (NASDAQ: NXTP) shares jumped 126% to $0.4525 after the company announced its NextFintech division received commitment for a $15 million strategic investment. 
Via Benzinga
Fulcrum Therapeutics to Present New Data from the Open Label Extension of Phase 2 ReDUX4 Study at the World Muscle Society (WMS) Congress in Halifax, Canada
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
U.S. Stock Futures Edge Lower Ahead Of Walmart, Home Depot Earnings
Pre-open movers 
Via Benzinga
Walmart, Home Depot And 3 Stocks To Watch Heading Into Tuesday
With US stock futures trading slightly lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Fulcrum Therapeutics Earnings Preview
  Fulcrum Therapeutics (NASDAQ:FULC) is set to give its latest quarterly earnings report on Thursday, 2022-08-11. Here's what investors need to know before the announcement. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
  
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
10 Biggest Price Target Changes For Monday
RBC Capital reduced Tesla, Inc. (NASDAQ: TSLA) price target from $1,175 to $1,100. Tesla shares fell 3.7% to $670.89 in pre-market trading. 
Via Benzinga
Mid-Afternoon Market Update: Dow Drops Over 600 Points; Fulcrum Therapeutics Shares Tumble
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping more than 600 points on Friday. 
Via Benzinga
91 Biggest Movers From Friday
Gainers RISE Education Cayman Ltd (NYSE: REDU) shares jumped 138.5% to settle at $3.41 on Friday. RISE Education announced expected timing for the completion of the merger with Dada Auto. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Mid-Day Market Update: Nasdaq Dips 400 Points; Cogent Biosciences Shares Jump
U.S. stocks traded lower midway through trading, with the Nasdaq Composite tumbling around 400 points on Friday. 
Via Benzinga
44 Stocks Moving In Friday's Mid-Day Session
Gainers Cogent Biosciences, Inc. (NASDAQ: COGT) shares jumped 77% to $8.79 after the company reported initial data from its ongoing Phase 2 APEX clinical trial. 
Via Benzinga
Mid-Morning Market Update: Markets Open Lower; US Inflation Rate Accelerates to 8.6%
U.S. stocks traded lower this morning, with the Dow Jones dropping more than 600 points on Friday. 
Via Benzinga
Looking Into Fulcrum Therapeutics's Return On Capital Employed
Benzinga Pro data, Fulcrum Therapeutics (NASDAQ:FULC) reported Q1 sales of $2.59 million. Earnings fell to a loss of $25.93 million, resulting in a 10.41% decrease from last quarter. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 73 stocks hit new 52-week lows. 
Via Benzinga
Earnings Preview: Fulcrum Therapeutics
Fulcrum Therapeutics (NASDAQ:FULC) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that Fulcrum... 
Via Benzinga
Fulcrum Therapeutics Earnings Conference Call Is Coming Up, Here's What You Need To Know
Fulcrum Therapeutics (NASDAQ:FULC) will host a conference call at 08:00 AM ET on May 9, 2022, to discuss Q1 2022 earnings results. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers 
Via Benzinga
The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.